DSM is an outsourcing manufacturing partner committed to meeting market demand globally with quality, regulatory excellence and innovations for sustainability. DSM offers preclinical/R&D through Phase I, II and III to commercial scale production for active pharmaceutical ingredients, mammalian cell cultures, microbial fermentation, and, sterile and solid dosage form manufacturing. In Pharma Chemicals, we cover the spectrum from clinical to commercial services to outsource active pharmaceutical ingredients (APIs), registered intermediates (RIs), and registered starting materials.
James E. Gregory, UPM Pharmaceuticals||October 7, 2015 Pharmaceutical and biopharmaceutical companies large and small are increasingly relying on third-party providers for support at all stages of drug development. To realize efficiencies, they are at the same time reducing the number of suppliers to a preferred few with whom they can form strategic partnerships.
Franklin Spriggs, Stephanie Mowery and Bo Kowalcyk, AIT Bioscience ||October 7, 2015 ADCs are a breakthrough cancer treatment that can deliver cytotoxins directly to cancer cells without the sweeping collateral damage of traditional chemotherapy.
Suhasini Sharma, Sciformix Corporation ||September 11, 2015 Global biologics market will expand to $250 billion annually by 2020, with biosimilars and non-original biologics commanding 4-10% of that market